National Healthcare Security Administration: By the end of June 2026, at least 100 key monitored easily resold and backflowed healthcare products will be included in the scope of intelligent supervision coverage.

The Office of the National Medical Security Administration issued a notice on further strengthening the intelligent supervision of excessive prescribing of drugs. The notice mentioned conducting pilot projects and exploring experiences. By the end of December 2025, in the pilot reform areas of intelligent supervision nationwide, at least 50 key monitored drugs that are prone to being sold back into medical insurance coverage will be included in the intelligent supervision scope. This will be gradually expanded to cover the entire province. By the end of June 2026, the medical insurance bureaus of all provinces, autonomous regions, municipalities directly under the central government, and corps will include at least 100 key monitored drugs that are prone to being sold back into medical insurance coverage in the intelligent supervision scope.